UA77295C2 - Liquid preparation comprising camptothecin derivative and pharmaceutical composition produced by freeze-drying - Google Patents

Liquid preparation comprising camptothecin derivative and pharmaceutical composition produced by freeze-drying Download PDF

Info

Publication number
UA77295C2
UA77295C2 UA20041109367A UA20041109367A UA77295C2 UA 77295 C2 UA77295 C2 UA 77295C2 UA 20041109367 A UA20041109367 A UA 20041109367A UA 20041109367 A UA20041109367 A UA 20041109367A UA 77295 C2 UA77295 C2 UA 77295C2
Authority
UA
Ukraine
Prior art keywords
liquid preparation
glycyl
group
preparation according
differs
Prior art date
Application number
UA20041109367A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of UA77295C2 publication Critical patent/UA77295C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
UA20041109367A 2002-04-16 2003-04-15 Liquid preparation comprising camptothecin derivative and pharmaceutical composition produced by freeze-drying UA77295C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002112864 2002-04-16
PCT/JP2003/004745 WO2003086471A2 (en) 2002-04-16 2003-04-15 Lyophilized and liquid preparations comprising a polysaccharide derivative of camptothecin

Publications (1)

Publication Number Publication Date
UA77295C2 true UA77295C2 (en) 2006-11-15

Family

ID=29243336

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20041109367A UA77295C2 (en) 2002-04-16 2003-04-15 Liquid preparation comprising camptothecin derivative and pharmaceutical composition produced by freeze-drying

Country Status (21)

Country Link
US (1) US20050215485A1 (enExample)
EP (1) EP1501549A2 (enExample)
JP (1) JP3927954B2 (enExample)
KR (1) KR100700963B1 (enExample)
CN (1) CN100544769C (enExample)
AR (1) AR039272A1 (enExample)
AU (1) AU2003223120B2 (enExample)
BR (1) BR0309283A (enExample)
CA (1) CA2480425A1 (enExample)
HR (1) HRP20040894A2 (enExample)
ME (1) MEP31308A (enExample)
MX (1) MXPA04010178A (enExample)
MY (1) MY136696A (enExample)
NO (1) NO20044964L (enExample)
PL (1) PL371677A1 (enExample)
RS (1) RS91204A (enExample)
RU (1) RU2315623C2 (enExample)
TW (1) TW200306314A (enExample)
UA (1) UA77295C2 (enExample)
WO (1) WO2003086471A2 (enExample)
ZA (1) ZA200408008B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1714653B1 (en) * 2004-02-13 2010-11-24 Kabushiki Kaisha Yakult Honsha Aqueous solution preparation containing a camptothecin
US20070207149A1 (en) 2004-04-27 2007-09-06 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
CA2612949C (en) 2005-07-14 2015-04-28 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
JP2007260275A (ja) * 2006-03-29 2007-10-11 Transcutaneous Technologies Inc イオントフォレーシス装置及びイオントフォレーシス投与用組成物
WO2011041003A2 (en) 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
AU2010264538B2 (en) 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
CN102764260B (zh) * 2011-04-30 2014-07-30 正大天晴药业集团股份有限公司 一种喜树碱衍生物的药物组合物及其制备方法
WO2013011598A1 (ja) * 2011-07-15 2013-01-24 コニカミノルタホールディングス株式会社 溶解助剤を利用したリポソーム含有製剤およびその製造方法
CN113304278A (zh) 2014-12-26 2021-08-27 日本化药株式会社 喜树碱类高分子衍生物的药物制剂
RU2726415C2 (ru) 2015-09-03 2020-07-14 Ниппон Каяку Кабусики Каися Фармацевтическая композиция, содержащая полимерное производное камптотецина
US10517961B2 (en) 2015-09-25 2019-12-31 ZY Therapeutics, Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
RU2018129760A (ru) * 2016-03-01 2020-04-01 Ниппон Каяку Кабусики Кайся Фармацевтический препарат, содержащий полимерное производное на основе камптотецина
CN109481691A (zh) * 2018-11-20 2019-03-19 珠海天香苑生物科技发展股份有限公司 吉西他滨-羧甲基多糖共轭物、制备方法及其用途
MX2024006239A (es) * 2021-11-26 2024-06-11 Astellas Pharma Inc Composicion farmaceutica solida que contiene el compuesto indocianina.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340817A (en) * 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
DK0540099T3 (da) * 1991-10-29 1996-06-17 Glaxo Wellcome Inc Vandopløselige camptothecinderivater
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
AR030207A1 (es) * 2000-04-07 2003-08-13 Daiichi Seiyaku Co Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma
AU2001271037A1 (en) * 2000-07-13 2002-01-30 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical compositions containing dds compounds
TWI313609B (en) * 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor

Also Published As

Publication number Publication date
KR100700963B1 (ko) 2007-03-28
AU2003223120A1 (en) 2003-10-27
EP1501549A2 (en) 2005-02-02
AU2003223120B2 (en) 2006-10-05
BR0309283A (pt) 2005-02-15
WO2003086471A2 (en) 2003-10-23
US20050215485A1 (en) 2005-09-29
PL371677A1 (en) 2005-06-27
AU2003223120A2 (en) 2003-10-27
KR20050000516A (ko) 2005-01-05
AR039272A1 (es) 2005-02-16
NO20044964L (no) 2004-11-15
CA2480425A1 (en) 2003-10-23
MY136696A (en) 2008-11-28
JP2005523329A (ja) 2005-08-04
RU2004133349A (ru) 2005-05-27
RU2315623C2 (ru) 2008-01-27
HRP20040894A2 (en) 2005-10-31
CN1646172A (zh) 2005-07-27
MXPA04010178A (es) 2005-06-08
JP3927954B2 (ja) 2007-06-13
TW200306314A (en) 2003-11-16
RS91204A (sr) 2006-12-15
ZA200408008B (en) 2005-06-13
CN100544769C (zh) 2009-09-30
WO2003086471A3 (en) 2004-04-15
MEP31308A (en) 2010-10-10

Similar Documents

Publication Publication Date Title
UA124259C2 (uk) Фармацевтичне одержання стабільного анти-pd-1 антитіла та його застосування в медицині
RU2315623C2 (ru) Жидкий препарат, содержащий производное кампототецина, и фармацевтическая композиция, получаемая путем лиофилизации препарата
KR101024511B1 (ko) 올리고펩티드 및 에테르화된 시클로덱스트린을 포함하는액상 제제
US20170202901A1 (en) Stable compositions of peptide epoxy ketones
JPH03193735A (ja) グリコペプチド系抗生物質の安定化組成物
WO2008023807A1 (fr) Composition pharmaceutique stabilisée
KR20250106301A (ko) 항-her3 항체-약물 접합체 조성물 및 이의 의약적 용도
DK2922530T3 (en) Caspofunginacetatformuleringer
US12491229B2 (en) Stabilized peptide composition
JP2005523329A5 (enExample)
KR20160115827A (ko) 인돌 화합물을 포함하는 제제 및 이의 제조 방법
CN114555085B (zh) 包含溶栓肽-四氢异喹啉缀合物的药物组合物
JP7423028B2 (ja) ボルテゾミブを含有する凍結乾燥医薬組成物
HK1079430B (en) Liquid preparation comprising oligopeptides and etherified cyclodextrin
JPH03240731A (ja) 制がん剤組成物